Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ReNeuron Group Plc Receives European, US Orphan Drug Designation For ReN003-DJ


Thursday, 29 Aug 2013 02:51am EDT 

Dow Jones reported that ReNeuron Group Plc said its ReN003 retinal stem cell therapy candidate for retinitis pigmentosa has been granted Orphan Drug Designation in both Europe and the U.S., adding that treatments with this designation benefit from commercial and regulatory advantages such as market exclusivity for 10 years. Orphan Drug Designation is typically granted to treatments that provide benefit to patients with rare diseases that are life-threatening or chronically debilitating. Treatments with this designation benefit from commercial and regulatory advantages such as market exclusivity for 10 years from approval in the disease concerned, against other treatments offering no greater therapeutic advantage. 

Company Quote

3.425
-0.05 -1.45%
12:08pm EDT